Alzheimer and Parkinson diagnoses in progranulin null mutation carriers in an extended founder family

Nathalie Brouwers, Karen Nuytemans, Julie Van Der Zee, Ilse Gijselinck, Sebastiaan Engelborghs, Jessie Theuns, Samir Kumar-Singh, Barbara A. Pickut, Philippe Pals, Bart Dermaut, Veerle Bogaerts, Tim De Pooter, Sally Serneels, Marleen Van Den Broeck, Ivy Cuijt, Maria Mattheijssens, Karin Peeters, Raf Sciot, Jean Jacques Martin, Patrick Cras & 6 others Patrick Santens, Rik Vandenberghe, Peter P. De Deyn, Marc Cruts, Christine Van Broeckhoven, Kristel Sleegers

Research output: Contribution to journalArticle

111 Citations (Scopus)

Abstract

Background: Progranulin gene (PGRN) haploinsufficiency was recently associated with ubiquitin-positive frontotemporal lobar degeneration linked to chromosome 17q21 (FTLDU-17). Objective: To assess whether PGRN genetic variability contributed to other common neurodegenerative brain diseases, such as Alzheimer disease (AD) or Parkinson disease (PD). Design: Mutation analysis of PGRN. Setting: Memory Clinic of the Middelheim General Hospital. Patients:Weanalyzed 666 Belgian patients with AD and 255 with PD. Main Outcome Measures: Results of PGRN sequencing, PGRN transcript analysis, short tandem repeat genotyping, and neuropathologic analysis. Results: We identified 2 patients with AD and 1 patient with PD who carried the null mutation IVS0 + 5G>C, which we reported earlier in an extensively characterized Belgian founder family, DR8, segregating FTLDU. Postmortem pathologic diagnosis of the patient with PD revealed both FTLDU and Lewy body pathologic features. In addition, we identified in PGRN only 1 other null mutation, the nonsense mutation p.Arg535X, in 1 patient with probable AD. However, in vitro analysis predicted a PGRN C-truncated protein, although it remains to be elucidated if this shortened transcript leads to haploinsufficiency. Conclusions: Our mutation data indicated that null mutations are rare in patients with AD (3/666=0.45%) and PD (1/255=0.39%). Also, AD and PD clinical diagnoses in patients who carry PGRN null mutations likely result from etiologic heterogeneity rather than PGRN haploinsufficiency.

Original languageEnglish (US)
Pages (from-to)1436-1446
Number of pages11
JournalArchives of Neurology
Volume64
Issue number10
DOIs
StatePublished - Oct 1 2007
Externally publishedYes

Fingerprint

Mutation
Parkinson Disease
Genes
Haploinsufficiency
Alzheimer Disease
Frontotemporal Lobar Degeneration
Lewy Bodies
Carrier
Gene
Alzheimer
Nonsense Codon
Brain Diseases
Ubiquitin
Protein C
General Hospitals
Neurodegenerative Diseases
Microsatellite Repeats
Alzheimer's Disease
Parkinson's Disease
Chromosomes

ASJC Scopus subject areas

  • Arts and Humanities (miscellaneous)
  • Clinical Neurology

Cite this

Brouwers, N., Nuytemans, K., Van Der Zee, J., Gijselinck, I., Engelborghs, S., Theuns, J., ... Sleegers, K. (2007). Alzheimer and Parkinson diagnoses in progranulin null mutation carriers in an extended founder family. Archives of Neurology, 64(10), 1436-1446. https://doi.org/10.1001/archneur.64.10.1436

Alzheimer and Parkinson diagnoses in progranulin null mutation carriers in an extended founder family. / Brouwers, Nathalie; Nuytemans, Karen; Van Der Zee, Julie; Gijselinck, Ilse; Engelborghs, Sebastiaan; Theuns, Jessie; Kumar-Singh, Samir; Pickut, Barbara A.; Pals, Philippe; Dermaut, Bart; Bogaerts, Veerle; De Pooter, Tim; Serneels, Sally; Van Den Broeck, Marleen; Cuijt, Ivy; Mattheijssens, Maria; Peeters, Karin; Sciot, Raf; Martin, Jean Jacques; Cras, Patrick; Santens, Patrick; Vandenberghe, Rik; De Deyn, Peter P.; Cruts, Marc; Van Broeckhoven, Christine; Sleegers, Kristel.

In: Archives of Neurology, Vol. 64, No. 10, 01.10.2007, p. 1436-1446.

Research output: Contribution to journalArticle

Brouwers, N, Nuytemans, K, Van Der Zee, J, Gijselinck, I, Engelborghs, S, Theuns, J, Kumar-Singh, S, Pickut, BA, Pals, P, Dermaut, B, Bogaerts, V, De Pooter, T, Serneels, S, Van Den Broeck, M, Cuijt, I, Mattheijssens, M, Peeters, K, Sciot, R, Martin, JJ, Cras, P, Santens, P, Vandenberghe, R, De Deyn, PP, Cruts, M, Van Broeckhoven, C & Sleegers, K 2007, 'Alzheimer and Parkinson diagnoses in progranulin null mutation carriers in an extended founder family', Archives of Neurology, vol. 64, no. 10, pp. 1436-1446. https://doi.org/10.1001/archneur.64.10.1436
Brouwers, Nathalie ; Nuytemans, Karen ; Van Der Zee, Julie ; Gijselinck, Ilse ; Engelborghs, Sebastiaan ; Theuns, Jessie ; Kumar-Singh, Samir ; Pickut, Barbara A. ; Pals, Philippe ; Dermaut, Bart ; Bogaerts, Veerle ; De Pooter, Tim ; Serneels, Sally ; Van Den Broeck, Marleen ; Cuijt, Ivy ; Mattheijssens, Maria ; Peeters, Karin ; Sciot, Raf ; Martin, Jean Jacques ; Cras, Patrick ; Santens, Patrick ; Vandenberghe, Rik ; De Deyn, Peter P. ; Cruts, Marc ; Van Broeckhoven, Christine ; Sleegers, Kristel. / Alzheimer and Parkinson diagnoses in progranulin null mutation carriers in an extended founder family. In: Archives of Neurology. 2007 ; Vol. 64, No. 10. pp. 1436-1446.
@article{6dc32f7710294e4daf03aad89c20c59a,
title = "Alzheimer and Parkinson diagnoses in progranulin null mutation carriers in an extended founder family",
abstract = "Background: Progranulin gene (PGRN) haploinsufficiency was recently associated with ubiquitin-positive frontotemporal lobar degeneration linked to chromosome 17q21 (FTLDU-17). Objective: To assess whether PGRN genetic variability contributed to other common neurodegenerative brain diseases, such as Alzheimer disease (AD) or Parkinson disease (PD). Design: Mutation analysis of PGRN. Setting: Memory Clinic of the Middelheim General Hospital. Patients:Weanalyzed 666 Belgian patients with AD and 255 with PD. Main Outcome Measures: Results of PGRN sequencing, PGRN transcript analysis, short tandem repeat genotyping, and neuropathologic analysis. Results: We identified 2 patients with AD and 1 patient with PD who carried the null mutation IVS0 + 5G>C, which we reported earlier in an extensively characterized Belgian founder family, DR8, segregating FTLDU. Postmortem pathologic diagnosis of the patient with PD revealed both FTLDU and Lewy body pathologic features. In addition, we identified in PGRN only 1 other null mutation, the nonsense mutation p.Arg535X, in 1 patient with probable AD. However, in vitro analysis predicted a PGRN C-truncated protein, although it remains to be elucidated if this shortened transcript leads to haploinsufficiency. Conclusions: Our mutation data indicated that null mutations are rare in patients with AD (3/666=0.45{\%}) and PD (1/255=0.39{\%}). Also, AD and PD clinical diagnoses in patients who carry PGRN null mutations likely result from etiologic heterogeneity rather than PGRN haploinsufficiency.",
author = "Nathalie Brouwers and Karen Nuytemans and {Van Der Zee}, Julie and Ilse Gijselinck and Sebastiaan Engelborghs and Jessie Theuns and Samir Kumar-Singh and Pickut, {Barbara A.} and Philippe Pals and Bart Dermaut and Veerle Bogaerts and {De Pooter}, Tim and Sally Serneels and {Van Den Broeck}, Marleen and Ivy Cuijt and Maria Mattheijssens and Karin Peeters and Raf Sciot and Martin, {Jean Jacques} and Patrick Cras and Patrick Santens and Rik Vandenberghe and {De Deyn}, {Peter P.} and Marc Cruts and {Van Broeckhoven}, Christine and Kristel Sleegers",
year = "2007",
month = "10",
day = "1",
doi = "10.1001/archneur.64.10.1436",
language = "English (US)",
volume = "64",
pages = "1436--1446",
journal = "Archives of Neurology",
issn = "0003-9942",
publisher = "American Medical Association",
number = "10",

}

TY - JOUR

T1 - Alzheimer and Parkinson diagnoses in progranulin null mutation carriers in an extended founder family

AU - Brouwers, Nathalie

AU - Nuytemans, Karen

AU - Van Der Zee, Julie

AU - Gijselinck, Ilse

AU - Engelborghs, Sebastiaan

AU - Theuns, Jessie

AU - Kumar-Singh, Samir

AU - Pickut, Barbara A.

AU - Pals, Philippe

AU - Dermaut, Bart

AU - Bogaerts, Veerle

AU - De Pooter, Tim

AU - Serneels, Sally

AU - Van Den Broeck, Marleen

AU - Cuijt, Ivy

AU - Mattheijssens, Maria

AU - Peeters, Karin

AU - Sciot, Raf

AU - Martin, Jean Jacques

AU - Cras, Patrick

AU - Santens, Patrick

AU - Vandenberghe, Rik

AU - De Deyn, Peter P.

AU - Cruts, Marc

AU - Van Broeckhoven, Christine

AU - Sleegers, Kristel

PY - 2007/10/1

Y1 - 2007/10/1

N2 - Background: Progranulin gene (PGRN) haploinsufficiency was recently associated with ubiquitin-positive frontotemporal lobar degeneration linked to chromosome 17q21 (FTLDU-17). Objective: To assess whether PGRN genetic variability contributed to other common neurodegenerative brain diseases, such as Alzheimer disease (AD) or Parkinson disease (PD). Design: Mutation analysis of PGRN. Setting: Memory Clinic of the Middelheim General Hospital. Patients:Weanalyzed 666 Belgian patients with AD and 255 with PD. Main Outcome Measures: Results of PGRN sequencing, PGRN transcript analysis, short tandem repeat genotyping, and neuropathologic analysis. Results: We identified 2 patients with AD and 1 patient with PD who carried the null mutation IVS0 + 5G>C, which we reported earlier in an extensively characterized Belgian founder family, DR8, segregating FTLDU. Postmortem pathologic diagnosis of the patient with PD revealed both FTLDU and Lewy body pathologic features. In addition, we identified in PGRN only 1 other null mutation, the nonsense mutation p.Arg535X, in 1 patient with probable AD. However, in vitro analysis predicted a PGRN C-truncated protein, although it remains to be elucidated if this shortened transcript leads to haploinsufficiency. Conclusions: Our mutation data indicated that null mutations are rare in patients with AD (3/666=0.45%) and PD (1/255=0.39%). Also, AD and PD clinical diagnoses in patients who carry PGRN null mutations likely result from etiologic heterogeneity rather than PGRN haploinsufficiency.

AB - Background: Progranulin gene (PGRN) haploinsufficiency was recently associated with ubiquitin-positive frontotemporal lobar degeneration linked to chromosome 17q21 (FTLDU-17). Objective: To assess whether PGRN genetic variability contributed to other common neurodegenerative brain diseases, such as Alzheimer disease (AD) or Parkinson disease (PD). Design: Mutation analysis of PGRN. Setting: Memory Clinic of the Middelheim General Hospital. Patients:Weanalyzed 666 Belgian patients with AD and 255 with PD. Main Outcome Measures: Results of PGRN sequencing, PGRN transcript analysis, short tandem repeat genotyping, and neuropathologic analysis. Results: We identified 2 patients with AD and 1 patient with PD who carried the null mutation IVS0 + 5G>C, which we reported earlier in an extensively characterized Belgian founder family, DR8, segregating FTLDU. Postmortem pathologic diagnosis of the patient with PD revealed both FTLDU and Lewy body pathologic features. In addition, we identified in PGRN only 1 other null mutation, the nonsense mutation p.Arg535X, in 1 patient with probable AD. However, in vitro analysis predicted a PGRN C-truncated protein, although it remains to be elucidated if this shortened transcript leads to haploinsufficiency. Conclusions: Our mutation data indicated that null mutations are rare in patients with AD (3/666=0.45%) and PD (1/255=0.39%). Also, AD and PD clinical diagnoses in patients who carry PGRN null mutations likely result from etiologic heterogeneity rather than PGRN haploinsufficiency.

UR - http://www.scopus.com/inward/record.url?scp=35348872039&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=35348872039&partnerID=8YFLogxK

U2 - 10.1001/archneur.64.10.1436

DO - 10.1001/archneur.64.10.1436

M3 - Article

VL - 64

SP - 1436

EP - 1446

JO - Archives of Neurology

JF - Archives of Neurology

SN - 0003-9942

IS - 10

ER -